65--Manufacture/Distributor Br-Philadelp
Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/09ffe41a0f4e4be1a08aae56e69e11ac/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking a Manufacture/Distributor Br-Philadelp. This service/item is typically used for drugs and biologicals. The notice includes a modification that adds NDC 51407-0426-12 to CLIN 0006 of the contract. For more information, contact DENISE TAUBMAN at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.

    Point(s) of Contact
    DENISE TAUBMAN215-737-8677
    DENISE.TAUBMAN@DLA.MIL
    Files
    Title
    Posted
    signed SPE2D221D0125P00002.pdf
    Lifecycle
    Title
    Type
    65--Manufacture/Distributor Br-Philadelp
    Currently viewing
    Special Notice
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    IBUPROFEN 400MG, 600MG, 800MG TABLETS NATIONAL CONTRACT
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking IBUPROFEN 400MG, 600MG, 800MG TABLETS. This medication is typically used for pain relief, reducing inflammation, and lowering fever. The notice is from the DEFENSE LOGISTICS AGENCY, DLA TROOP SUPPORT. The primary contact for this procurement is Denise Taubman (denise.taubman@dla.mil, 2157376877) and the secondary contact is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778). The notice includes AMENDMENT 00009 to incorporate telecommunication clauses into the solicitation.
    Bicalutamide 50MG tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Dextroamphetamine/Amphetamine National Contract
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    Lansoprazole Capsules
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Lansoprazole capsules, specifically 30MG in 100 count bottles. This procurement aims to establish a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable supply of this essential pharmaceutical item. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or 215-737-6031, and are encouraged to set up automated notifications for updates on the solicitation through the DLA Bid Board System and Sam.Gov.
    MODIFICATION TO CONTRACT
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is modifying a contract with DLA TROOP SUPPORT. The modification to the contract is for an undisclosed service or item. The primary contact for this notice is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 2157378677. The details of the modification are not provided in the document.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    Fexofenadine HCL Follow On MOD P00002
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    Dextroamphetamine/Amphetamine National Contract
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is being modified to change the address for Acetris. This contract is related to the procurement of medical and surgical instruments, equipment, and supplies. The place of performance for this contract is Monmouth Junction, NJ 08852, USA. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 215-737-8677.
    Telmisartan Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product, to be delivered over multiple contract years. This solicitation, identified as SPE2D2-24-R-0015, requires compliance with various federal regulations, including the submission of a Subcontracting Plan for large businesses and adherence to Federal Acquisition Regulation (FAR) clauses concerning ethics and subcontracting practices. Telmisartan is crucial for managing hypertension and ensuring a reliable pharmaceutical supply is vital for military personnel's health. Interested vendors should submit their electronic proposals via the Defense Logistics Agency Internet Bid Board System (DIBBS) and can contact Courtney Hunter-Stangler at 215-737-6845 or via email at Courtney.Hunter-Stangler@dla.mil for further information.